Efficacy and Safety of Tobevibart (VIR-3434) Alone or in Combination With Elebsiran (VIR-2218) in Participants With Chronic Hepatitis Delta Virus Infection: Week 48 Endpoint Analysis From the Phase 2 SOLSTICE Trial

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Efficacy and Safety of Tobevibart (VIR-3434) Alone or in Combination With Elebsiran (VIR-2218) in Participants With Chronic Hepatitis Delta Virus Infection: Week 48 Endpoint Analysis From the Phase 2 SOLSTICE Trial

	AASLD 2025 Nov 7-11 Wash DC Tarik Asselah,1 Published simultaneously in NEJM, attached pdf. Download the PDF here